File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: multicentre East Asian and Dutch database comparison

TitlePathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: multicentre East Asian and Dutch database comparison
Authors
Issue Date29-Aug-2022
PublisherBritish Journal of Surgery Society
Citation
British Journal of Surgery, 2022, v. 109, n. 12, p. 1312-1318 How to Cite?
Abstract

Background

Patients with different ethnic and genetic backgrounds may respond differently to anticancer therapies. This study aimed to assess whether patients with oesophageal squamous cell carcinoma (OSCC) treated with neoadjuvant chemoradiotherapy (nCRT) in East Asia had an inferior pathological response compared with patients treated in Northwest Europe.

Methods

Patients with OSCC who underwent nCRT according to the CROSS regimen (carboplatin and paclitaxel with concurrent 41.4 Gy radiotherapy) followed by oesophagectomy between June 2012 and April 2020 were identified from East Asian and Dutch databases. The primary outcome was pCR, defined as ypT0 N0. Groups were compared using propensity score matching, adjusting for sex, Charlson Co-morbidity Index score, tumour location, cT and cN categories, interval between nCRT and surgery, and number of resected lymph nodes.

Results

Of 725 patients identified, 133 remained in each group after matching. A pCR was achieved in 37 patients (27.8 per cent) in the Asian database and 58 (43.6 per cent) in the Dutch database (P = 0.010). The rate of ypT1–4 was higher in Asian than Dutch data (66.2 and 49.6 per cent; P = 0.004). The ypN1–3 rate was 44.4 per cent in the Asian and 33.1 per cent in the Dutch data set. Clear margins were achieved in 92.5 per cent of Asian and 95.5 per cent of Dutch patients.

Conclusion

Regional differences in responses to CROSS nCRT for oesophageal cancer were apparent, the origin of which will need evaluation.


Persistent Identifierhttp://hdl.handle.net/10722/331651
ISSN
2023 Impact Factor: 8.6
2023 SCImago Journal Rankings: 2.148
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorEyck, BM-
dc.contributor.authorGao, X-
dc.contributor.authorYang, Y-
dc.contributor.authorvan der Wilk, BJ-
dc.contributor.authorWong, I-
dc.contributor.authorWijnhoven, BPL-
dc.contributor.authorLiu, J-
dc.contributor.authorLagarde, SM-
dc.contributor.authorLam, KO-
dc.contributor.authorHulshof, MCCM-
dc.contributor.authorLi, ZG-
dc.contributor.authorLaw, S-
dc.contributor.authorChao, YK-
dc.contributor.authorvan Lanschot, JJB-
dc.date.accessioned2023-09-21T06:57:42Z-
dc.date.available2023-09-21T06:57:42Z-
dc.date.issued2022-08-29-
dc.identifier.citationBritish Journal of Surgery, 2022, v. 109, n. 12, p. 1312-1318-
dc.identifier.issn0007-1323-
dc.identifier.urihttp://hdl.handle.net/10722/331651-
dc.description.abstract<p>Background</p><p>Patients with different ethnic and genetic backgrounds may respond differently to anticancer therapies. This study aimed to assess whether patients with oesophageal squamous cell carcinoma (OSCC) treated with neoadjuvant chemoradiotherapy (nCRT) in East Asia had an inferior pathological response compared with patients treated in Northwest Europe.</p><p>Methods</p><p>Patients with OSCC who underwent nCRT according to the CROSS regimen (carboplatin and paclitaxel with concurrent 41.4 Gy radiotherapy) followed by oesophagectomy between June 2012 and April 2020 were identified from East Asian and Dutch databases. The primary outcome was pCR, defined as ypT0 N0. Groups were compared using propensity score matching, adjusting for sex, Charlson Co-morbidity Index score, tumour location, cT and cN categories, interval between nCRT and surgery, and number of resected lymph nodes.</p><p>Results</p><p>Of 725 patients identified, 133 remained in each group after matching. A pCR was achieved in 37 patients (27.8 per cent) in the Asian database and 58 (43.6 per cent) in the Dutch database (<em>P</em> = 0.010). The rate of ypT1–4 was higher in Asian than Dutch data (66.2 and 49.6 per cent; <em>P</em> = 0.004). The ypN1–3 rate was 44.4 per cent in the Asian and 33.1 per cent in the Dutch data set. Clear margins were achieved in 92.5 per cent of Asian and 95.5 per cent of Dutch patients.</p><p>Conclusion</p><p>Regional differences in responses to CROSS nCRT for oesophageal cancer were apparent, the origin of which will need evaluation.</p>-
dc.languageeng-
dc.publisherBritish Journal of Surgery Society-
dc.relation.ispartofBritish Journal of Surgery-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titlePathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: multicentre East Asian and Dutch database comparison-
dc.typeArticle-
dc.identifier.doi10.1093/bjs/znac314-
dc.identifier.scopuseid_2-s2.0-85143552096-
dc.identifier.volume109-
dc.identifier.issue12-
dc.identifier.spage1312-
dc.identifier.epage1318-
dc.identifier.eissn1365-2168-
dc.identifier.isiWOS:000846910900001-
dc.identifier.issnl0007-1323-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats